Pabriga, William A.

HRN: 06-57-88  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/25/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
07/25/2026
08/01/2026
IVT
2.25g
Q8
CRBSI
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  BloodstreamSkin & Soft Tissue    Compliance to guidelines: